ENDRA Life Sciences Q1 net loss $1.0M; pivots to metabolic disease diagnostics, plans FDA de novo trial

ENDRA Life Sciences Inc.

2026-Q1 EPS reported -$1.86 vs consensus -$1.25 ▼ miss (-48.3%)

Net loss $1.0M in Q1 2025 vs $2.8M in Q1 2024; operating expenses down 46% to $1.5M.
Cash burn improved to $1.2M in Q1 2025 from $1.7M in Q1 2024; cash at April 30 was $2.5M after $0.8M ATM raise.
Strategic pivot to point-of-care liver fat diagnostics for metabolic disease; redesigned TAEUS system with AI.
Revised FDA regulatory strategy: plans prospective multicenter trial of ~250 subjects for De Novo submission.
Two new patents issued in China, bringing IP portfolio to 84 total.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.